GeoVax Labs (GOVX) announced the completion of an interim data review by the Data Safety Monitoring Board (DSMB) for the ongoing Phase 2 clinical trial of GEO-CM04S1, GeoVax’s dual-antigen n “This is very exciting news,” commented David Dodd, GeoVax President and CEO, “The outcome of the DSMB interim review appears to support our view of GEO-CM04S1 as a potentially superior COVID-19 vaccine booster within the CLL patient population. Within the CLL and other immune-compromised patient populations, more robust and durable protective immunity is needed, as provided by potential next-generation vaccines such as GEO-CM04S1 that induce both strong T cell and antibody responses.”
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-movingbreaking financial news Try Now>>
See the top stocks recommended by analysts >>
Read More on GOVX:
- GeoVax Labs Reports Improved Earnings and Strategic Progress
- GeoVax Labs reports Q3 EPS (91c), consensus ($1.48)
- Pinterest, Cisco upgraded: Wall Street’s top analyst calls
- GeoVax Labs initiated with a Buy at Alliance Global Partners
- Geovax Labs, Inc. (GOVX) Q3 Earnings Cheat Sheet
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
